Trial Profile
A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin LAR
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly; Neuroendocrine tumours
- Focus Pharmacokinetics
- Sponsors Camurus
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 12 Jul 2016 According to a Camurus media release, status changed from active, no longer recruiting to completed.
- 17 May 2016 According to a Camurus media release, the company anticipates the results of this trial in the second quarter of 2016.